Capstone Investment Advisors’s Charles River Laboratories CRL Stock Holding History

Capstone Investment Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-300	Closed	-$55.4K	–	1450
2024 Q4	$55.4K	Buy	300 +100	+50%	+$19.3K	﹤0.01%	1753
2024 Q3	$39.4K	Sell	200 -100	-33%	-$20.8K	﹤0.01%	1823
2024 Q2	$62K	Hold	300	–	–	﹤0.01%	1932
2024 Q1	$81.3K	Sell	300 -100	-25%	-$23.9K	﹤0.01%	2165
2023 Q4	$94.6K	Buy	+400	New	+$78.7K	﹤0.01%	1940
2023 Q3	–	Sell	-500	Closed	-$105K	–	2125
2023 Q2	$105K	Hold	500	–	–	﹤0.01%	1690
2023 Q1	$101K	Buy	+500	New	+$113K	﹤0.01%	1369
2022 Q2	–	Sell	-100	Closed	-$28K	–	1879
2022 Q1	$28K	Hold	100	–	–	﹤0.01%	1921
2021 Q4	$38K	Sell	100 -1,000	-91%	-$389K	﹤0.01%	1758
2021 Q3	$454K	Buy	1,100 +700	+175%	+$291K	﹤0.01%	1583
2021 Q2	$148K	Buy	+400	New	+$134K	﹤0.01%	1530

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capstone Investment Advisors's CRL Position: Q1 2025 in Review

Capstone Investment Advisors sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 1,043 shares — an estimated $193K sold.

Capstone Investment Advisors first reported a position in CRL in Q1 2016 and held it in 13 quarters. The position peaked at $2.62M in Q1 2017. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

Capstone Investment Advisors reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
Capstone Investment Advisors sold 1,043 Charles River Laboratories shares in Q1 2025, an estimated $193K.
Capstone Investment Advisors first reported a position in Charles River Laboratories in Q1 2016 and held it in 13 quarters.
Capstone Investment Advisors's Charles River Laboratories position peaked at $2.62M in Q1 2017.
561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Capstone Investment Advisors's 13F filing for Q1 2025, filed 15 May 2025.